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When thinking about congruence, several synonyms come
to mind: similarity, correspondence, equivalence, resem-
blance, analogy, comparison; certainly the antonym:
(dissimilarity) does not. So let us compare two relevant,
seemingly parallel ideas, concepts especially in the
discipline of integrative and complementary medicine.
In recent discussions, it proved useful to examine in
some depth, what may seem superficial but that probably
represents a true and future linkage or congruence.
A quick reading of published works does suggest con-
gruence perhaps not immediate, but clearly interdepen-
dence and sometimes overlap. Perhaps for one of the
two, they dig like an archeologist, discover like a pale-
ontologist whereas the other reaps the harvest of those
diggings and seeks to understand what all the pieces
mean and how they fit together: one discovers shards, the
other glues them together. And so it goes, ethnophama-
cology and evidence based approaches can link and share
characteristics.
That kind of analogy emerged and was best revealed at
the XX Symposium of Medicinal Plants of Brazil and the
X International Congress of Ethnopharmacology in Sao
Paolo. Questions posed by Michael Heinrich (United
Kingdom) and that of participants in his workshop
noted a flavor of ethnopharmacology that in my opinion
often coalesces with the evidence based component. Two
questions: can one identify ethnopharmacological treat-
ments for metabolic problems? Or, does this affect what
evidence-based approaches seek to do? Of course it does.
Evidence-based approaches should readily capture the
essence of a well characterized plant or animal extract
derived from long years of practice in a particular culture
and then subject that well characterized extract to an
easily designed model for further rigorous experimenta-
tion: in vitro; animal models; well defined clinical trials,
that are empirical. In a sense, one discipline discovers
whereas the other experiments and seeks to provide
information through the use of ideally randomized,
clinical trials that withstand all the rigors of evidence
based approaches. These then are dependent on the
discoveries and information transfer provided by the
dedicated ethnopharmacologists—they discover and
CAM puts the discoveries to work. They are mutually
dependent; there is a linkage!
Introducing the pertinent work in Sao Paolo, according
to Alves and Rosa (1–4) (Federal University of Paraiba)
‘The World Health Organization (WHO), estimates that
as many as 80% of the world’s more than six billion
people rely primarily on animal and plant-based medi-
cines’. Starting from the viewpoint of bioprospecting as a
CAM Frontier, I proposed the following. The healing of
human ailments by using therapeutics based on medicines
from animals or ultimately derived from them is known
as zootherapy. Zootherapy has a marked geographical
distribution and substantial cultural origins. Despite their
importance, analyses of the therapeutic use of animals
and animal parts have been neglected, when compared
with plants (both are referred to as herbals which are
usually defined as plants!). However within complemen-
tary and alternative medicine, zootherapy has been
explored from the viewpoint of evidence based (5),
because the literature appears ‘glutted’ with products
derived from plants (6). Both sources of natural products
provide extensive sources of new CAM approaches that
will emerge as important for future applications, includ-
ing compounds isolated from marine microorganisms and
phytoplankton, green algae, brown algae, red algae, fungi
and certain well-known marine and terrestrial animals:
sponges, coelenterates, bryozoans, molluscs, tunicates,
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properly cited.echinoderms, earthworms and leeches (7,8). There has
been an emphasis on new compounds (677 in 2002),
together with their relevant biological activities, source
organisms and country of origin. Thus syntheses that
lead to the revision of structures or stereochemistries
have been included (114), and any first total syntheses of
a marine natural product (9–13). Using animal products
as components of bioprospecting has implications for
medicines the environment, economy, public health and
culture.
What was reported in Sao Paolo that may serve to
clarify more about congruence? I recently chaired a brief
assembly in Sao Paulo: ‘Use of medicinal plants around
the world’ where there was substantial enthusiasm.
According to Hajdu from the University of Szeged,
Hungary, Provenir is a semi-isolated Indian community
in the Bajo Paragua Indian Reservation of the Bolivian
Amazon. Altogether, 135 plants from the ‘traditional
pharmacopoeia’ of Porvenir were listed and collected,
among them 62 species have been utilized to treat
diarrhea, dysentery, gastric-ache, gastric ulcer, gastritis,
vomiting, constipation, appendicitis, liver diseases and
are also used to help in weight loss. Moreover, based on
the frequency and consistency of usage, some species
appear suitable for further development into licenses,
cheap, locally available medicine. Of the species, 25% are
considered good subjects for research of biologically
active new natural products. Similarly, Barboza presented
a complete checklist of the medicinal flora and an ana-
lysis of its diversity as observed in Argentina. In another
approach, this time to veterinary practice, Cesio and
colleagues from Uruguay reported a different concern.
Helminthiasis is a major animal health concern in live-
stock production, causing important economic losses.
The resistance against commercially synthetic antihelmin-
tics forces the search for alternative therapies. They
concluded that the ethnobotanical approach for the
selection of plants was successful, as at least 75% of
tested plants were active. They yielded potential raw
materials for veterinary phytopharmaceuticals.
Finally, Giovannini and Heinrich from London pre-
sented interesting conclusions on Xki yoma (our medi-
cine) and xki tienda (patent medicine) as an interface
between traditional and modern medicine among the
Mazatecs of Oaxaca, Mexico. They concluded that when
there is an investigation of a complex pluralistic medical
system, an approach that goes beyond the externally
imposed dichotomic categories of traditional and modern
medicine can be extremely useful to enlighten us on other
dimensions that underlie the local use of medicines.
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